Merck & Co. continues to demonstrate strong market resilience. Our proprietary Annual Review model indicates robust fundamentals despite macroeconomic headwinds. Key catalysts include product innovation in AI and strategic cost optimization.
We utilize a blended approach of DCF (50%) and EV/EBITDA multiples (50%). Our WACC assumption is 8.1% based on a beta of 1.42.